Company intelligence / Profile preview
Sam Chun Dang Pharm Co., Ltd.
Seoul, Seoul, South Koreamarketscreener.com ↗
- Ownership
- Private
- Employees
- ~409
- Development stage
- Commercial
01
Overview
Sam Chun Dang Pharm has a strong commercial presence in ophthalmology as Korea’s #1 player by market share. Its pipeline includes an aflibercept biosimilar for wet AMD with distribution deals across Europe and North America. The company’s oral semaglutide generic uses its proprietary S-PASS platform to bypass formulation patents; bioequivalence studies began in early 2025 with anticipated market entry as soon as late 2026. Other programs target neuralgia and xerophthalmia at earlier clinical stages
- Therapeutic areas
- GastroenterologyCardiovascularOphthalmologyEndocrinologyNeurologyInfectious Diseases
- Modalities
- Small moleculesBiosimilars
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Apotex(Canada) – licensing of Eylea® biosimilar for CanadaUnnamed distributors – exclusive agreements covering UK,Belgium,the Netherlands,Norway,
Portugal,
Sweden,Greece,Ireland,
Finland,
Austria,Germany,
Italy,
Spain,and SwitzerlandFresenius Kabi–Eylea®biosimilar commercialization in US & Latin America.
Beyond the preview
Go deeper on Sam Chun Dang Pharm Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sam Chun Dang Pharm Co., Ltd..